인터페론 치료에 반응이 없었던 소아의 만성 B형 간염에 대한 라미부딘의 치료 효과
Effect of Lamivudine Treatment on Chronic Hepatitis B Infection in Children Unresponsive to Interferon
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Interferon is a widely used treatment for chronic hepatitis B in children. However, additional treatment options are needed because more than 50% of hepatitis B patients are unresponsive to interferon. Although lamivudine is widely used to treat hepatitis B, there are few studies on the effect of lamivudine in hepatitis B patients unresponsive to interferon. Methods: Eight interferon unresponsive patients (6 males and 2 females) were treated with lamivudine (3 mg/kg/day, maximum 100 mg/day) from 6∼12 months after interferon treatment was discontinued among 33 children with chronic hepatitis B. They were treated with interferon (interferon α-2b, 10 MU/m2 or pegylated interferon 1.5μg/kg) for 6 months from January 2000 to December 2007 at the Pusan National University Hospital. The medical records were analyzed retrospectively. Results: The age at treatment with interferon and lamivudine was 4.9±3.1 and 6.1±3.2 years, respectively. The serum ALT level before treatment with interferon was 148.1±105.8 IU/L and the log HBV-DNA PCR mean value was 6.95±0.70 copies/mL. The serum ALT level after treatment with interferon was 143.1±90.4 IU/L and the log HBV-DNA mean PCR value was 6.46±2.08. HBeAg negativization occurred in 2 patients. For all patients, normalization of the serum ALT levels and HBeAg seroconversion (except 2 patients with HBeAg negativization) occurred at 7.4±2.1 and 7.9±2.1 months respectively after lamivudine treatment. The HBV-DNA PCR became negative in 7 patients (87.5%) at 2.4±2.8 months. Complete response was achieved in 7 patients and no recurrence was observed in 2 patients for 3 years after the completion of treatment. Five patients are still under treatment for a mean treatment duration of 24.4±9.1 months. In one patient, viral breakthrough occurred and the treatment was stopped. Conclusion: The number of patients was small, however, lamivudine treatment in patients with chronic hepatitis B who were unresponsive to interferon was highly effective.
Abstract
Purpose: Interferon is a widely used treatment for chronic hepatitis B in children. However, additional treatment options are needed because more than 50% of hepatitis B patients are unresponsive to interferon. Although lamivudine is widely used to treat hepatitis B, there are few studies on the effect of lamivudine in hepatitis B patients unresponsive to interferon. Methods: Eight interferon unresponsive patients (6 males and 2 females) were treated with lamivudine (3 mg/kg/day, maximum 100 mg/day) from 6∼12 months after interferon treatment was discontinued among 33 children with chronic hepatitis B. They were treated with interferon (interferon α-2b, 10 MU/m2 or pegylated interferon 1.5μg/kg) for 6 months from January 2000 to December 2007 at the Pusan National University Hospital. The medical records were analyzed retrospectively. Results: The age at treatment with interferon and lamivudine was 4.9±3.1 and 6.1±3.2 years, respectively. The serum ALT level before treatment with interferon was 148.1±105.8 IU/L and the log HBV-DNA PCR mean value was 6.95±0.70 copies/mL. The serum ALT level after treatment with interferon was 143.1±90.4 IU/L and the log HBV-DNA mean PCR value was 6.46±2.08. HBeAg negativization occurred in 2 patients. For all patients, normalization of the serum ALT levels and HBeAg seroconversion (except 2 patients with HBeAg negativization) occurred at 7.4±2.1 and 7.9±2.1 months respectively after lamivudine treatment. The HBV-DNA PCR became negative in 7 patients (87.5%) at 2.4±2.8 months. Complete response was achieved in 7 patients and no recurrence was observed in 2 patients for 3 years after the completion of treatment. Five patients are still under treatment for a mean treatment duration of 24.4±9.1 months. In one patient, viral breakthrough occurred and the treatment was stopped. Conclusion: The number of patients was small, however, lamivudine treatment in patients with chronic hepatitis B who were unresponsive to interferon was highly effective.
참고문헌 (20)
- Torre D, "Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis", Clin Infect Dis, 23, pp.131~137 (1996)
- Jonas MM, "Areias JA, Schwarz KB, et al. Clinical trial of lamivudine in children with chronic hepatitis B", N Engl J Med, 346, pp.1706~1713 (2002)
- 고재성, "소아 만성 B형 간염의 Interferon Alfa 치료 후 혈청학적, 조직학적 소견의 변화", 대한소아소화기영양학회지, 3, pp.56~62 (2000)
- 김홍권, "만성 B형 간염 환아에서 interferon-alpha 치료의반응 예측 인자 분석", Korean Journal of Pediatrics, 43(4), pp.514~519 (2000), 대한소아과학회
- Choe BH, "Long-term therapeutic efficacy of lamivudine compared to interferon-alpha in children with chronic hepatitis B: the younger the better", J Pediatr Gastroenterol Nutr, 44, pp.92~98 (2007)
- Boni C, "Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B", J Clin Invest, 102, pp.968~975 (1998)
- Lai CL, "A one-year trial of lamivudine for chronic hepatitis B", N Engl J Med, 339, pp.61~68 (1998)
- Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States", N Engl J Med, 341, pp.1256~1263 (1999)
- 장유철, "소아 만성 B형 간염에서 라미부딘 치료의 3년 누적 치료 반응과 장기 지속성", 대한소아소화기영양학회지, 7(2), pp.197~207 (2004), 대한소아소화기영양학회
- Schiff ER, "Lamivudine and 24 weeks of lamivudine", interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders, 2003, pp.38, 818~826
- Hartman C, "Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon", Pediatr Infect Dis J, 22, pp.224~229 (2003)
- Hartman C, "Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon", J Pediatr Gastroenterol Nutr, 43, pp.494~498 (2006)
- Leung NW, "Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy", Hepatology, 33, pp.1527~1532 (2001)
- "Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C", J Gastroenterol Hepatol, 15, pp.825~841 (2000)
- Lok AS, "Chronic hepatitis B", Hepatology, 34, pp.1225~1241 (2001)
- Liaw YF, "Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group", Gastroenterology, 119, pp.172~180 (2000)
- Dikici B, "Davutoglu M, Yagci RV, et al. Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha- interferon combination and alpha-interferon alone", Pediatr Int, 44, pp.517~521 (2002)
- Selimoglu MA, "Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children", Pediatr Int, 44, pp.404~408 (2002)
- Saltik-Temizel IN, "Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection", J Clin Gastroenterol, 39, pp.68~70 (2005)
- Ikeda K, "Someya T, Hosaka T, et al. Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase", Am J Med, 119, pp.977~985 (2006)